1. Home
  2. BIRK vs RYTM Comparison

BIRK vs RYTM Comparison

Compare BIRK & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Birkenstock Holding plc

BIRK

Birkenstock Holding plc

HOLD

Current Price

$39.42

Market Cap

7.0B

Sector

N/A

ML Signal

HOLD

Logo Rhythm Pharmaceuticals Inc.

RYTM

Rhythm Pharmaceuticals Inc.

HOLD

Current Price

$115.68

Market Cap

5.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BIRK
RYTM
Founded
1774
2008
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.0B
5.8B
IPO Year
2023
2017

Fundamental Metrics

Financial Performance
Metric
BIRK
RYTM
Price
$39.42
$115.68
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
14
14
Target Price
$61.43
$131.14
AVG Volume (30 Days)
1.7M
682.0K
Earning Date
05-13-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
28.34
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$13.71
$55.34
Revenue Next Year
$14.30
$86.06
P/E Ratio
$17.48
N/A
Revenue Growth
N/A
N/A
52 Week Low
$31.33
$74.50
52 Week High
$53.53
$122.20

Technical Indicators

Market Signals
Indicator
BIRK
RYTM
Relative Strength Index (RSI) 46.98 61.49
Support Level $37.57 $98.59
Resistance Level $41.89 $122.20
Average True Range (ATR) 1.80 5.42
MACD 0.12 0.83
Stochastic Oscillator 44.71 82.89

Price Performance

Historical Comparison
BIRK
RYTM

About BIRK Birkenstock Holding plc

Birkenstock is a German footwear brand known for comfort-focused, timeless designs, with 76% of 2022 sales coming from its top five iconic models. Products are made in Europe using sustainable, mostly locally sourced materials. The brand combines orthopedic function with everyday style, appealing to a broad audience. The Americas account for 52% of sales, EMEA 37%, with the remainder coming from Asia-Pacific, which has also the higher future growth expectations.

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.

Share on Social Networks: